Literature DB >> 24125523

Thrombosis in pediatric cancer: identifying the risk factors to improve care.

Uma Athale1.   

Abstract

Cancer-associated thromboembolism (TE) is now a frequent complication in children. The reported prevalence varies from up to 16% of symptomatic to 40% of asymptomatic TE in children with cancer. Compared to the general pediatric population, children with cancer who develop TE have an increased risk of death, TE recurrence, TE-related morbidity and higher potential for utilization of health care resources. TE is preventable with anticoagulation therapy. With over 80% cure rates of childhood cancer, strategies for prevention as well as for early diagnosis and optimal treatment of TE in children with cancer are of major importance. An understanding of the risk factors predisposing children with cancer for development of TE will facilitate development of preventive and therapeutic strategies.

Entities:  

Mesh:

Year:  2013        PMID: 24125523     DOI: 10.1586/17474086.2013.842124

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  3 in total

Review 1.  Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021.

Authors:  Anna Falanga; Benjamin Brenner; Alok A Khorana; Charles W Francis
Journal:  Res Pract Thromb Haemost       Date:  2022-07-01

2.  Antithrombotic prophylaxis in a patient with nephrotic syndrome and congenital protein S deficiency.

Authors:  Andrea Artoni; Serena Maria Passamonti; Alberto Edefonti; Francesca Gianniello; Vittorio Civelli; Ida Martinelli
Journal:  Ital J Pediatr       Date:  2016-02-29       Impact factor: 2.638

3.  Thrombosis and Anticoagulant Therapy Among Pediatric Cancer Patients: Real-Life Data.

Authors:  Hasan Hashem; Momen Zeineddin; Rayan Bater; Nisreen Amayiri; Wiam Al Qasem; Bilasan Hammo; Iyad Sultan; Rama AlMasri; Hikmat Abdel-Razeq
Journal:  Cureus       Date:  2021-12-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.